Orgametril® [Lynestrenol]

Drug should be administered orally, washing down with a small amount of water or other liquid. If the reception of the next pill is delayed, the woman should take the pill as soon as she remembered about it, except for the case when the delay in reception is more than 24 hours.

The first day of the cycle is the first day of menstrual bleeding.

Polymenorrhea: 5 mg (1 tab.) / Day from 14 to 25 days of the menstrual cycle.

Menorrhagia and Metrorrhagia: on 10 mg (2 tab.) / days within 10 days. Usually, bleeding stops within a few days after starting the drug. The course of treatment should be repeated over the next 3 menstrual cycles of 5 mg (1 tab.) Daily from 14 to 25 days of each menstrual cycle. If the therapy performed is ineffective, then additional diagnostic and therapeutic measures should be taken.

Some cases of primary or secondary amenorrhea or oligomenorrhea: Treatment should be started with estrogen, for example, 20-50 μg of ethinyl estradiol per day for 25 days. Against the background of estrogen administration, Orgametril is prescribed in 5 mg (1 tab.) / Day from 14 to 25 days of the menstrual cycle. After the end of the medication, menstrual bleeding usually begins after 3 days. Treatment continues (second cycle), starting from day 5, counting from the onset of bleeding: an estrogen drug is prescribed from day 5-25 of the menstrual cycle, orgametril is prescribed from day 14-25. The course of treatment should be repeated in at least one more cycle.

Endometriosis: on 5-10 mg (1-2 tab.) per day for at least 6 months in continuous mode.

Some cases of endometrial carcinoma: on 30-50 mg (6-10 tab.) per day for long periods.

Benign breast diseases: 5 mg (1 tab.) per day from 14 to 25 days of the menstrual cycle for at least 3-4 months.

To suppress ovulation, ovulatory pain and menstruation; dysmenorrhea: taking the drug Orgametril in a dose of 5 mg (1 tab.) per day should be started from the 1st day of the menstrual cycle, but no later than the 5th day of the menstrual cycle. Treatment may continue for many months (without interruption). If, during the treatment, breakthrough vaginal bleeding appears, the dose of the drug can be increased to 10-15 mg (2-3 tab.) Per day for 3-5 days.

To delay normal menstruation: taking the drug in 5 mg (1 tab.) per day should begin 2 weeks before the expected date of the onset of menses. If treatment is started less than 1 week before the menstruation date, then the dose of the drug should be increased - up to 10-15 (2-3 tab.) Per day. However, in this case, a delay of more than 1 week is undesirable. The likelihood of breakthrough bleeding from the vagina increases with a late start of treatment. For this reason, it is not recommended to start treatment if less than 3 days remain before the expected menstruation comes.

Addition to estrogen replacement therapy in perimenopause and postmenopause to prevent endometrial hyperplasia: Orgametril is prescribed at 2.5-5 mg (1 / 2-1 tab.) Daily for 12-15 days per month (for example, during the first 2 weeks of each month) in this case, estrogen replacement therapy can be carried out in a continuous mode in the least effective dose.

The drug is contraindicated for use in pregnancy.

The safety of the drug use Orgametril during lactation has not yet been established.

Treatment should be interrupted if test results indicate abnormal liver function.

When taking drugs containing estrogen and / or progestogen, especially in women with a history of pregnant chloasma, chloasma is sometimes observed. Women who are prone to chloasma should avoid exposure to skin sunlight or artificial UV radiation.

Taking sex hormones can affect specific laboratory tests. In many patients during treatment with Orgametril, it is possible to increase the level of LDL in the blood and lower the level of HDL. Changes in the parameters of liver function, carbohydrate metabolism, blood clotting system are possible.

With long-term treatment, systematic medical examinations are indicated; control of lipid and carbohydrate metabolism, bilirubin concentration, transaminases, coagulation system. The frequency and nature of systematic medical examinations depend on the circumstances in each individual case and should be determined in accordance with the clinical opinion, but at least 1 time in 6 months.

Due to the effect of Lynestrenol on the level of the globulin that binds sex hormones, Orgametril may show some androgenic activity. This can be expressed in mild signs of virilization (mainly acne or seborrhea).

Epidemiological studies have identified a connection with the use of progestogen in combination with estrogen with an increase in the incidence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). Although the clinical significance of this data for Lynestrenol without an estrogen component is unknown. In the case of thrombosis, you should stop taking the drug Orgametril. You should also consider the need to stop taking the drug Orgametril in case of prolonged immobilization due to surgery or disease. Women with a history of thromboembolic disease should be informed of the possibility of their recurrence.

It is necessary to constantly monitor the condition of patients with circulatory disorders (as well as, if they are in history), since the risk of certain cardiovascular diseases or cerebrovascular conditions increases slightly when oral estrogen / progestin contraceptives are taken.

While taking the drug Orgametril is recommended to limit the intake of fats and carbohydrates (which is especially important for women with initially high body mass).

In case of diabetes mellitus, the glycemic profile should be monitored (an increase in insulin dose may be required).

With a predisposition to hypertension, it is necessary to control blood pressure (to reduce fluid intake to 1.5-2 l / day).

In the case of dysfunctional uterine bleeding in women of reproductive age, it is recommended to begin therapy after therapeutic and diagnostic curettage of the uterus.

The ineffectiveness of therapy (recurrence of bleeding and endometrial hyperplastic processes) requires clarification of the causes of bleeding.

With a long delay of menstruation during therapy with the drug Orgametril, ectopic pregnancy should be excluded.

Orgametril contains lactose as an auxiliary substance. Therefore, this drug should not be administered to patients with rare hereditary disorders, such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption.

Influence on ability to drive motor transport and control mechanisms

Since the drug may cause dizziness, patients should exercise caution when driving or using other vehicles.

Symptoms: nausea, vomiting.

Treatment: conducting symptomatic therapy.